A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Ireland Limited.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
6actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated based on a business decision by the Sponsor.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-13 | actual | When the study began enrolling |
| Primary completion | 2026-01-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-29 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Narcolepsy
Interventions
- Drug: JZP441
- Drug: Matching Placebo
Primary outcome
what the primary-completion date above is the date OFMean sleep latency of the first 4 sessions of the Maintenance of Wakefulness Test
measured 1, 3, 5, and 7 hours after the first dose of study intervention
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed